Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer

Part of paid clinical trials in Charleston, South Carolina.

Sponsor
Medical University of South Carolina
Study ID
NCT00287963
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy, such as topotecan and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of topotecan when given together with vinorelbine in treating patients with recurrent lung cancer.

Key Dates

Start date
Feb 29, 2004
Status verified
May 2018
Primary completion
Jan 31, 2010
Completion
Jan 31, 2010

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vinorelbine + topotecan

Primary Outcome Measure

Maximum tolerated dose [ Time Frame: Cycle 1 (up to day 21) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Hollings Cancer Center at Medical University of South CarolinaCharlestonSouth Carolina29425-

Find similar trials in Charleston, SC

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Hollings Cancer Center at Medical University of South Carolina· Charleston, SC

Related Studies